Table 1 Clinical and demographic characteristics of the patients at the time of ETN measurement

Female (%)

62 (64)

47 (57)

0.32

Age (years), mean (SD)

7.5 (3.6)

8.6 (3.8)

0.037

Height (cm), mean (SD)

122 (23)

128 (239)

0.11

Weight (kg), mean (SD)

26.5 (13.0)

28.6 (13.7)

0.27

BMI, kg/ m²

16.6 (2.8)

16.5 (2.5)

0.77

BSA (m²), mean (SD)

0.94 (0.31)

1.00 (0.33)

0.17

Disease duration (years), mean (SD)

2.3 (2.4)

3.2 (2.8)

0.019

Diagnosis

0.74

 Oligoarthritis, persistent

17 (18)

18 (22)

 Oligoarthritis, extended

15 (15)

14 (17)

 Polyarthritis, RF-negative

57 (49)

40 (48)

 Polyarthritis, RF-positive

2 (2)

1 (1)

 Enthesitis related arthritis

4 (4)

7 (8)

 Psoriatic arthritis

1 (1)

2 (2)

 Undifferentiated arthritis

1 (1)

1 (1)

Uveitis, n (%)

9 (9)

2 (2)

0.066

Inflammatory bowel disease, n (%)

1 (1)

1(1)

0.99

Previous bDMARD, n (%)

10 (10)

15 (18)

0.13

 Etanercept

7

10

 Adalimumab

3

4

 Infliximab

2

4

 Tocilizumab

0

2

Concomitant treatment n (%)

 Other sDMARDs

6 (6)

32 (39)

< 0.001

 Prednisolone

4 (4)

7(8)

0.23

ESR (mm/h), mean (SD)

13.2 (14.0)

12.1 (12.1)

0.61

CRP (mg/l), mean (SD)

4.9 (12.6)

5.9 (13.5)

0.63

JADAS10, mean (SD)

10.0 (5.6)

9.7 (5.8)

0.56

PaGA, mean (SD)

3.3 (2.6)

2.6 (2.2)

0.10

PhGA, mean (SD)

3.1 (1.8)

2.7 (1.9)

0.14

HLA-B27 positive, n (%)

27 (28)

25 (30)

0.58

ANA, n (%)

31 (32)

23 (28)

0.54

Erosions, n (%)

21 (22)

16 (19)

0.60